AIRFLOW-2 randomized, sham-controlled one-year data accepted by AJRCCM MINNEAPOLIS, Aug 19, 2019 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today multiple peer-reviewed publications that provide further evidence of the safety, clinical effectiveness, and mechanisms of action of Targeted Lung Denervation (TLD) therapy in COPD. The company’s dNerva® Lung […]
A first for Temple University Hospital and U.S. Patients MINNEAPOLIS, June 10, 2019 – Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, announced the first treatments in the AIRFLOW-3 pivotal trial, the first interventional COPD trial to target reduction in COPD exacerbations as a primary endpoint. Two U.S. patients were successfully treated […]
Novel program provides reimbursement for TLD therapy in France MINNEAPOLIS, April 28, 2019 – Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, has received acceptance from the Haute Autorité de Santé (HAS, the French health technology assessment agency) into its Forfait Innovation program. The program is designed to fast-track novel medical devices […]
Market Development Veteran Lisa Rogan Joins Nuvaira’s Executive Team MINNEAPOLIS, Feb 11, 2019 – Nuvaira, a developer of novel therapeutic medical devices to treat obstructive lung diseases, announced today it has closed a $79 million equity financing led by U.S. Venture Partners, with Endeavour Vision, Qiming Venture Partners, Lightstone Ventures and Richard King Mellon Foundation […]
6500 Wedgwood Road North, Ste. 100
Minneapolis, MN 55311
Nuvaira Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).
Ce dispositif médical est un produit de santé réglementé qui porte, au titre de cette réglementation, le marquage CE. En France, le système de Dénervation Ciblée des Poumons dNerva ne fait pas l’objet d‘un dépôt de dossier de remboursement par les organismes d’assurances maladie.